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Repeated exposure to low-level blast is a characteristic of a few select occupations and
there is concern that such occupational exposures present risk for traumatic brain injury.
These occupations include specialized military and law enforcement units that employ
controlled detonation of explosive charges for the purpose of tactical entry into secured
structures.The concern for negative effects from blast exposure is based on rates of oper-
ator self-reported headache, sleep disturbance, working memory impairment, and other
concussion-like symptoms. A challenge in research on this topic has been the need for
improved assessment tools to empirically evaluate the risk associated with repeated expo-
sure to blast overpressure levels commonly considered to be too low in magnitude to cause
acute injury. Evaluation of serum-based neurotrauma biomarkers provides an objective
measure that is logistically feasible for use in field training environments. Among candidate
biomarkers, ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) has some empirical support
and was evaluated in this study. We used daily blood draws to examine acute change in
UCH-L1 among 108 healthy military personnel who were exposed to repeated low-level
blast across a 2-week period. These research volunteers also wore pressure sensors to
record blast exposures, wrist actigraphs to monitor sleep patterns, and completed daily
behavioral assessments of symptomology, postural stability, and neurocognitive function.
UCH-L1 levels were elevated as a function of participating in the 2-week training with
explosives, but the correlation of UCH-L1 elevation and blast magnitude was weak and
inconsistent. Also, UCH-L1 elevations did not correlate with deficits in behavioral measures.
These results provide some support for including UCH-L1 as a measure of central nervous
system effects from exposure to low-level blast. However, the weak relation observed
suggests that additional indicators of blast effect are needed.
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INTRODUCTION
Repeated exposure to low-level blast is a characteristic of a few
select occupations and there is concern that such chronic expo-
sure presents risk for traumatic brain injury (1). The hypothe-
sized injury to the brain from repeated blast overpressure may
be analogous to the mounting recognition of problems from
multiple sports-related concussions and sub-concussive impacts
(2, 3). Observations are similar for symptomology associated
with sports-related concussion and symptomology associated with
exposure to repeated blast (4); however, there is a key difference
from sports-related concussion, or even sub-concussive impacts,
in that there is no physical impact to the head from routine occu-
pational blast exposure. This difference has prompted a unique
line of research on effects from occupational exposure to low-
level blast. A challenge in this research has been the need for
improved assessment tools, particularly objective markers suitable
for field settings, where transient acute effects are most likely to
occur (5). The objective of this report is to evaluate the utility of a
blood-based neurotrauma biomarker, ubiquitin carboxy-terminal
hydrolase-L1 (UCH-L1), as a marker of neurological effects from
occupational blast exposure in humans.
Human exposure to blast can occur in a military combat envi-
ronment with acute effects on the brain and resulting clinical
conditions. Occupational exposure to blast also occurs outside
the combat environment in military and specialized law enforce-
ment training. For military personnel, this includes training in
artillery/mortar firing, grenades and distraction devices (e.g., flash
bangs), a variety of shoulder-fired weapons (e.g., high powered
rifles), and explosive breaching. For non-military personnel, spe-
cialized law enforcement units may not train with artillery or
mortar weaponry, but they do train with explosive breaching. In
the case of breaching, operators construct an explosive charge and
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detonate it while at relatively close distances. This tactical tech-
nique is used to create a breach in a locked door or wall to afford
rapid entry to a secured structure. To employ explosive breach-
ing effectively, personnel train with explosive charges resulting in
hundreds or thousands of exposure to low-level blast. In the case
of those designated as instructors, who have the responsibility of
training others, routine exposures to blast can number in the tens
of thousands. Safety protocols for such exposure typically stipu-
late that blast overpressure for personnel should not exceed 4 psi
in any single event. Those protocols are followed through a priori
estimation of overpressure levels, which has been a more practi-
cal method than actual measurement of pressure experienced by
operators. It was not until relatively recently that pressure sensor
technology could be worn by individuals without interfering with
operations.
The 4 psi safety threshold is based on the force observed to rup-
ture the unprotected human tympanic membrane. The threshold
for an overpressure injury to the human central nervous system
(CNS) is unknown due to the lack of exposure magnitude data
available for acute events resulting in clinically diagnosed injuries.
The potential for that threshold to change with multiple low-
level exposures, or tens of thousands of such exposures, has only
recently been considered. There is no known lower limit of expo-
sure magnitude that can be considered irrelevant in the context of
many repeated exposures. For the purposes of the study reported
here, “low-level blast” is not defined as a quantified range of over-
pressure values but rather as blast used in standardized training
protocols, settings in which clinical diagnosis of primary blast
injury does not occur. Now that technological advances make it
feasible to measure individualized exposures to occupational blast,
there is an opportunity to empirically evaluate effects that are sus-
pected to follow from repeated low-level blast exposure in humans.
The challenge is identifying effective outcome measures.
A survey of symptomology among professional breachers
showed elevated rates of self-reported headache, sleep disturbance,
and working memory impairment, among other symptoms (4).
This symptomology was also reported by breachers in the survey
to interfere with daily function but it was not concomitant with
any clinical diagnosis of head injury, only with repeated expo-
sure to blast. Further, the greater the number of reported blast
exposures, the more frequent and severe the reported symptomol-
ogy. A parallel association of symptomology and degree of blast
exposure is seen within a sample of military personnel who have
been diagnosed with concussion (6). This pattern of concussion-
like symptomology and association with occupational blast raises
the concern that such repeated exposures, even at low-level mag-
nitude, entail risk to the CNS. To date, there have been several
efforts to study the relation of occupational blast exposure and
CNS damage in humans (7–9). Those studies used more objective
assessments than self-report of symptoms, including measures of
sleep disruption, vestibular stability, neurocognitive performance,
and serum-based neurotrauma biomarkers.
Kelley et al. (7) equipped 18 military breachers with wrist-worn
actigraphy units for the duration of a 2-week explosive breaching
training protocol. Actigraphy uses accelerometers to continuously
record limb motion, which reliably reflects periods of activity and
periods of sleep and its use for assessing sleep patterns in normal,
healthy adult populations is endorsed by the American Academy of
Sleep Medicine (10). Although subjects reported greater daytime
sleepiness in conjunction with explosive breaching, actigraphy
assessments did not reveal a corresponding change in sleep/wake
data. Baker et al. (8) used a variety of empirically validated vestibu-
lar assessments and neurocognitive assessments to examine 14
civilian law enforcement breachers completing a 10-day explosives
techniques instructor course. The behavioral assessments were
administered by physicians and trained technicians and were aug-
mented by a computer-based neurocognitive assessment. Overall,
these assessments did not show deficits associated with breach-
ing blast exposure. The most recent of these studies (9) employed
serum-based neurotrauma biomarkers alongside computer-based
neurocognitive assessment with 19 soldiers during a 2-week explo-
sive entry course, and reported results showed some association
between low-level blast exposure, deficits in neurocognitive per-
formance, and neurotrauma biomarker elevation. However, evi-
dence for that association was isolated to a few individuals and
based on composite measures, combining multiple behavioral
measures and multiple biomarkers into single outcomes. Each
of these studies cited a key limitation from the low number of
available subjects and none included individually measured blast
overpressure. It is notable that the study employing serum-based
neurotrauma biomarkers showed the clearest association between
low-level blast exposure and outcome in objective measures (9).
The present study expands available evidence by using a relatively
large sample size and by measuring the magnitude of blast expo-
sure in conjunction with a concurrent serum-based neurotrauma
biomarker.
Ubiquitin carboxy-terminal hydrolase-L1 was the targeted bio-
marker for evaluation in the present study, given both empirical
and observational support in the current literature suggesting a
correlation with sub-concussive head impact. A recent review of
biomarkers for mild traumatic brain injury in blood identified
UCH-L1 as a candidate with empirical support (11), and a study
of UCH-L1 in sub-concussive sports-related head impacts showed
UCH-L1 increased with participation in collegiate level Ameri-
can football (12). Evidence of epigenetic changes to the ubiquitin
pathway among patients with blast-related mild traumatic brain
injury also suggests that there may be changes in the UCH-L1
proteomic marker following exposure to blast (13). Furthermore,
increases in serum UCH-L1 have been reliably observed <1 h fol-
lowing trauma, even among persons with mild injury severity
and no Glasgow Coma Scale deficit (14). This rapid change was
also observed in the study of UCH-L1 and sports-related sub-
concussive head impacts (12). Similar to observations of rapid
appearance of UCH-L1 after brain injury, UCH-L1 has also been
observed to rapidly diminish in serum after concussion in a mili-
tary sample (Carr et al., under review) as well as after more severe
injury (15). The low-level blast exposure study by Tate et al. (9)
employed serum-based neurotrauma biomarkers and described
biomarker “spikes” in their repeated measures paradigm. These
observations support the likelihood that changes in UCH-L1 level
following mild insult to the brain would be transient and could
serve to reflect day-to-day variations in environmental exposure.
The prospective observational study reported here examined
daily sampling of peripheral blood for UCH-L1 changes in
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conjunction with measurement of repeated exposure to low-level
blast. Blast-related effects were evaluated from normal healthy
individuals in field research paradigms rather than a clinical set-
ting. As such, effects were believed to be inherently small and
were expected to be subject to individual differences and factors
beyond the control available in laboratory experimental para-
digms. Nonetheless, exposure to blast is hypothesized to result
in acute elevations in serum UCH-L1 concentrations, even in
the relatively low-level blast experienced in training paradigms
for explosive breaching. However, this low-level blast environ-
ment does not typically result in acute diagnosable injury, so
the magnitude of an association between UCH-L1 and low-level
blast exposure is expected to be limited. This study maximized
the hypothesized effect by enrolling participants with a history of
blast exposure, which was expected to magnify effects in a manner
similar to multiple sports-related concussions.
MATERIALS AND METHODS
PARTICIPANTS
The protocol for this study was reviewed and approved by the
Naval Medical Research Center and Walter Reed Army Institute
of Research Institutional Review Boards. Across three separate
sites, 108 male, active duty military personnel provided written
informed consent to participate in this study while engaged in
training as either students or instructors. Prior to initiation of
the study, leadership from each site gave authorization for subject
recruitment and research activity during 2 weeks of standardized
training exercises. Training programs at all three sites were desig-
nated as advanced courses, requiring prior experience in explosive
breaching as prerequisite for entry. Therefore, all participants had
prior exposure to low-level blast overpressure. All individuals who
were enrolled as students or designated as instructors for the train-
ing programs were eligible to participate in the study. To maintain
group integrity and avoid isolating individuals during training, no
exclusion criteria were used.
During study enrollment, research participants provided self-
report of health history information, including history of blast
exposure and head injury, as well as experience with explosive
breaching. In data collection on training days with blast expo-
sure, participants were instrumented with two pressure sensors
to record blast parameters for each individual during training
exercises. At the end of every training day, regardless of blast expo-
sure, participants had blood drawn, and completed behavioral
measures of symptomology, postural stability, and computer-
based neurocognitive performance. Participants also wore wrist
actigraphs continuously throughout the 2-week period to mon-
itor sleep. At the time of this study, no females participated in
these training programs. Participants were compensated $25 per
blood draw, as authorized under Department of Defense policy
for research participation by military personnel on duty (DoDI
3216.02, 2011). Participant characteristics for the three sites are
listed in Table 1.
TRAINING ENVIRONMENTS
The three sites were similar in that each site employed breaching
blast with dismounted personnel across a 2-week period. The sites
trained personnel for different operations and had differences in
Table 1 | Demographic characteristics of study participants.
Site 1 Site 2 Site 3 Total
N 47 28 33 108
Age (years old) 25 (SD=3.8) 33 (5.2) 31 (4.9) 29 (5.9)
Prior head injury (yes/no) 23% (of sample) 41% 42% 34%
Prior blast exposure
(yes/no)
75% (of sample) 65% 79% 74%
Prior breaching
exposurea
40–99 100–199 40–99 40–99
aHistory of breaching exposure was assessed by a 7-level ordinal scale item with
the following response levels for number of explosive breaches experienced: 0,
1–9, 10–39, 40–99, 100–199, 200–399, or 400+. Responses were scored as val-
ues 0–6 and the descriptor in the table represents the level that corresponded to
the average of scores.
the frequency and type of explosive charges used. Figure 1 shows
a 2-week time period with depiction of training days and blast
exposure days for each site. Figure 1 labels training days with serial
numbers (“Sessions”). Data are reported according to Session.
BLAST MEASUREMENT
Overpressure from explosive blast was measured by pressure sen-
sors (micro Data Acquisition System, µDAS; Applied Research
Associates, Inc.) mounted on each subject’s helmet above left and
right ear cups. The helmet is considered to be the best place to
measure pressures in a study of traumatic brain injury because the
sensors are close to the brain and the helmet provides a consis-
tent spacing and orientation for the pressure measurements. The
system is designed to continuously monitor the environment for
changes in ambient pressure and is triggered to record data when
a threshold of 0.4 psi is exceeded on either sensor. This threshold
was chosen based on the technological specifications of the sensors
as well as considerations for signal to noise ratio in the interpre-
tation of sensor data output. For each triggered blast event, the
µDAS recorded the time of the event trigger, the peak pressure
(maximum overpressure reached during the blast event), and the
impulse energy (integral of overpressure over time throughout the
blast event). For each day of blast exposure, the number of trig-
gered events, the highest recorded peak pressure, and the highest
recorded impulse energy were logged for each participant.
For the analyses in this report, data used for each blast expo-
sure event were the averages of measurements from left and right
sensors. The rationale for averaging the measurements from sen-
sors mounted on the left and right sides of the helmet was to
address potential confounds introduced by the physical relation
between the sensors and blast wave path. For example, two per-
sons equipped with only one helmet-mounted sensor and who are
at equivalent distance from an open field blast may yield different
recorded pressures if one person’s sensor is exposed to the direct
path of the blast wave (reflective pressure) and the other person’s
head is turned, putting that sensor at a right angle to the path of
the blast wave (incident pressure) (16). A sensor in the shadow
of the helmet would likely yield lower pressure magnitude, even
though the two individuals may have experienced equivalent levels
of pressure.
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FIGURE 1 | Representation of training schedule and days of blast
exposure across a 2-week period for each of the three study
sites. Training days are labeled with serial Session numbers, with
Sites 1 and 3 showing 10 Sessions and Site 2 showing 9 Sessions.
Sessions with blast exposure are indicated by a jagged line
surrounding the Session serial number. Group-level blast was
recorded in 7 of 10 Sessions at Site 1, 7 of 9 Sessions at Site 2, and 4
of 10 Sessions at Site 3.
BLOOD COLLECTION AND UCH-L1 ASSAY
Peripheral blood draw was taken at the end of each training day,
which was generally late afternoon and approximately the same
time each day. Due to the observational nature of this protocol,
collecting research measurements in context of standard military
training, the time between blast exposure and blood draw was not
subject to control but all measurements were taken within 8 h from
the most recent exposure to blast that day (on the days in which
blast occurred). Blood was drawn from each subject on each day
regardless of blast exposure that day, so some Sessions will reflect
UCH-L1 concentration with no blast exposure in the preceding
24 h. Blood samples were processed for serum on site and frozen
at−80°C until analysis.
Ubiquitin carboxy-terminal hydrolase-L1 concentration was
measured in serum samples by Banyan Biomarkers prototype CL
assay, a sandwich ELISA. Samples were assessed in duplicate with
96-well plates coated with a capture antibody specific to UCH-L1.
Plates were then washed and a second biomarker-specific antibody
(detection antibody) was added, which created the “sandwich.”
The detection antibody was conjugated to horseradish peroxidase.
The plates were then washed and a substrate was introduced that
was converted by the enzyme attached to the detection antibody
into a chemiluminescent signal whose intensity was measured elec-
tronically. The chemiluminescent signal is directly proportional to
the amount of detection antibody and biomarker present.
Determination of the biomarker concentration in a specimen
sample is performed by comparing the signal intensity from the
unknown sample to a standard curve created from a series of
calibrators of known biomarker concentration run on the same
96-well plate as the unknown sample. Specimen samples were
tested using the same volume and under the same conditions as
those of the calibrators. Quality control samples consisting of a
known concentration of biomarker in a representative matrix were
included on each plate to allow for confirmation of expected assay
performance. Results are reported in picogram per milliliter.
ADDITIONAL SUPPORTING MEASURES
At the end of each training day, subjects also completed daily
assessments of health symptoms, neurocognitive performance,
and postural stability. Subjects reported health symptoms using
a paper-and-pencil inventory of 32 items associated with con-
cussion (Table 2). This inventory was similar to the Rivermead
instrument (17) but with additional items and responses solicited
in context of breaching exercises rather than concussion injury.
Responses were made on a 5-level Likert-type scale, ranging from
0 (symptom “not experienced at all”) to 4 (“severe problem”).
Table 2 | Inventory of health symptoms related to concussion.
Headaches Forgetfulness, poor
memory
Poor coordination/
clumsiness
Feelings of dizziness Poor concentration Change in taste/smell
Nausea and/or vomiting Taking longer to
think
Loss of or increased
appetite
Easily upset by loud noise Blurred vision Difficulty making
decisions
Difficulty localizing sound Easily upset by
bright lights
Slowed thinking
Sleep disturbance Double vision Difficulty getting
organized
Fatigue, tiring more easily Restlessness Easily overwhelmed by
things
Being irritable, easily
angered
Ringing in ears Light-headedness
Feeling depressed or sad Pain in ears Feeling disoriented
Feeling frustrated or
impatient
Fullness in ears Numbness or tingling
in body
Feeling anxious or tense Loss of balance
Postural stability was assessed by force platform measurement
(Biosway Clinical Test for Sensory Integration of Balance, Biodex
Medical Systems, Inc., Shirley, NY, USA) (18, 19). Subjects main-
tained steady posture for 30 s in each of in four conditions: eyes
open on firm surface, eyes closed on firm surface, eyes open on
dynamic surface (foam pad), and eyes closed on dynamic surface.
Each test yields an index score (“sway”) based on the standard devi-
ation of center of gravity deviations in any direction, as sampled
every 50 ms.
Computer-based neurocognitive testing was administered with
a version of the Automated Neuropsychological Assessment Met-
rics (ANAM) TBI Battery (20) and the Defense Automated Neu-
robehavioral Assessment (DANA) (21). The ANAM TBI Battery
subtests assess different cognitive abilities and are selected to be
sensitive to effects of brain injury (22). This battery has been
used elsewhere in research with similar populations and proto-
cols (9; Carr et al., under review). The DANA battery evolved
from development work for the ANAM TBI Battery but was
designed for application on a handheld device rather than desktop
or laptop computer. ANAM and DANA subtests involve visually
presented stimuli and computer mouse or stylus responses, which
are recorded by the computer and scored for accuracy and response
time. Instructions to subjects are to be both “fast and accurate.”
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These test paradigms are known to show large practice effects (23),
yielding large improvements in performance within the first two
or three trials. Accordingly, at least two practice trials were con-
ducted before baseline performance to mitigate practice effects
and improve sensitivity of these measures.
In addition to the methods described here, additional blood
draws and computer-based neurocognitive assessments were com-
pleted but they were not administered equivalently at all three sites
or were not administered on a daily basis (e.g., pre/post sampling
conducted only before and after the 2-week session). Those data
are not reported here. Wrist actigraphy was used to monitor sleep
patterns to assess potential confounds from sleep disruption and
was not a primary outcome measure in this study. Those data are
also not reported here.
ANALYSES
A criterion for the planned analyses of daily changes in UCH-L1
concentration was that subjects have their blood drawn at least
once in the protocol before exposure to blast in order to establish
a baseline for each individual. There were three individuals (from
Site 2) in the sample of 108 who did not meet this criterion, so
they were not included in the analyses.
In the primary analysis of serum UCH-L1 concentrations and
correspondence of UCH-L1 change to recorded blast exposures,
we compared a specific day in the 2-week training protocols to
baseline. This analysis approach was used because the observa-
tional design conducted within operational training paradigms
was expected to yield differences between individuals in exposure
to blast and other relevant environmental factors. The associa-
tion between UCH-L1 change and blast was expected to be most
identifiable on a day in which there was group-level exposure to
blast and group-level increase in UCH-L1. This exposure in com-
bination with increases in the marker suggests influence from an
environmental factor, mostly likely to be blast. Our approach of
comparing a specific training Session to the baseline Session was
used to control for confounds, such as days with no blast exposure
or exposure for only part of the overall group of subjects.
Baseline levels of UCH-L1 (picogram per milliliter) were
expected to be low, entirely or mostly below assay thresholds (i.e.,
below assay limit of quantification or limit of detection). When
UCH-L1 was not detected at the limit of detection (30.0 pg/mL), a
replacement value of 15.0 pg/mL was assigned (midpoint between
limit of detection and 0) (24). When UCH-L1 was detected but was
below limit of quantification (60.0 pg/mL), a replacement value of
45 pg/mL was assigned (midpoint between limit of quantifica-
tion and limit of detection). Inter-individual variance in absolute
concentrations across timepoints was managed by normalizing
UCH-L1 concentrations. UCH-L1 values at each timepoint were
expressed in terms of percentage of baseline level for each individ-
ual (12), thereby affording comparison of relative within-subject
change rather than absolute UCH-L1 changes.
Linear regression analyses were used to examine the association
between UCH-L1 change and blast magnitude. Characterizing the
magnitude of blast can be approached in a variety of methods,
especially when there are multiple blasts within the measured
period as in these data. Among various accepted measures of blast
exposure (e.g., peak pressure, peak impulse, incident pressure,
reflective pressure), it is unknown presently which measure (or
composite measure) is the most important in the hypothesized
effect on the CNS. However, it is known that these different mea-
sures will positively correlate with each other. We selected highest
recorded peak pressure of the day as the measure to represent blast
magnitude. Our rationale was based on the pressure sensors’ high
sampling rate and ability to capture peak pressure values, and also
the similarity between a timepoint-specific peak and a “traumatic”
event, which underlies the hypothesized neurotrauma-induced
change in UCH-L1.
The primary analysis, examining if UCH-L1 variance in the Ses-
sion with the greatest group-level UCH-L1 increase is accounted
for by blast magnitude, was supplemented with two secondary
analyses. One secondary analysis examined the Session with great-
est blast magnitude for a reflection in UCH-L1 concentration. The
other secondary analysis examined UCH-L1 on the final day of
blast exposure, regardless of group-level UCH-L1 increase or blast
magnitude. These analyses were considered secondary because
they do not address the question of UCH-L1 increase in relation to
blast as clearly as the primary analysis. For normal healthy individ-
uals, it is not yet demonstrated that UCH-L1 will reliably increase
following blast, even for the occasion of a relatively high levels of
blast in a training paradigm. Assessment of UCH-L1 on the final
day of multiple days with repeated blast exposure may reflect a
cumulative exposure to blast (i.e., multiple sub-concussive blast
events), rather than the acute effect hypothesized for this study. It
may be that a single low-level environmental exposure event may
not yield acute neurotrauma but, instead, predispose the CNS to be
more vulnerable to neurotrauma in a subsequent low-level envi-
ronmental exposure event. In such case, a transient marker like
UCH-L1 may reflect an increase after multiple events rather than
a single sub-concussive event but that was outside the scope of this
report.
In other supporting analyses, we examined reversals of UCH-
L1 increase and correspondence between UCH-L1 increase and
demographic factors. When change in UCH-L1 was observed in
our analyses, we compared UCH-L1 from the Session with blast
exposure to the first subsequent Session in which there was no blast
exposure. This comparison leveraged the relatively rapid decline
in UCH-L1 following a mild traumatic event and could offer addi-
tional evidence that UCH-L1 elevations observed were associated
with blast exposure. Observations of UCH-L1 change may be
reflected in individual characteristics of past history of exposure
to blast or head injury as well as acute change in symptomology,
postural stability, or neurocognitive performance. Observation of
behavioral change concurrent with UCH-L1 change would have
implications for inferences drawn from these data,but this research
paradigm is not associated with any clinical injury and behavioral
changes that would be clinically relevant were not expected. We
looked for subtle changes in these performance variables, but with
the expectation that such changes would not be distinct from vari-
ance due to factors other than blast exposure (e.g., performance
effort, practice effect).
RESULTS
In repeated measures of the 108 subjects, 10 Sessions for 2 of the
3 groups and 9 Sessions for the remaining group, a total of 1016
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blood samples were taken and assayed for UCH-L1. Three subjects
did not meet baseline criterion of no acute blast exposure prior to
the first blood draw and therefore were not included in analyses,
resulting in a total of 992 samples included in the analysis. Of the
992 UCH-L1 assays, 317 samples (32%) had UCH-L1 at detectable
levels and 71 samples (7%) showed UCH-L1 at quantifiable levels,
ranging from 60.3 to 277.7 pg/mL. Of the 105 subjects included in
the analysis, 18 individuals (17% of the overall sample) showed no
detectable UCH-L1 at any Session. Within daily assessment Ses-
sions, the average time between last blast exposure and blood draw
was 2 h 39 min, with a minimum case of 28 min and a maximum
case of 7 h 17 min.
For two of the three sites, the Session that met criterion for
comparison to baseline (i.e., greatest UCH-L1 and group expo-
sure to blast) clearly differed from the other Sessions (Figure 2).
Site 1 did not have a single clear comparison day. To include Site 1
data in analyses, we selected Session 8 for comparison with base-
line, due to the relatively high level of UCH-L1 measured, the
increase in level relative to the preceding day [Site 1 Session 8 vs.
Session 7, t (44)= 3.13, p= 0.003], and similarity of occurring in
the second week of study (comparable to the Sites 2 and 3). For
each of these Sites, the Session selected for comparison to baseline
showed that >40% of subjects showed increase in UCH-L1 rela-
tive to the previous day (Figure 3), suggesting the best potential for
examining a group-level phenomenon rather than an individual
phenomenon.
In the primary analysis, we examined the association between
UCH-L1 change and the greatest recorded peak pressure in blast
exposures from Session 8 for Sites 1 and 2 and Session 9 for Site
3. To quantify the association between UCH-L1 concentration
and magnitude of blast, we conducted a simple linear regression
FIGURE 2 | Normalized UCH-L1 concentrations (relative to individual
baseline) for each Session of the study at each of the three sites. Error
bars represent standard error. For two of the three sites, there is a Session
in the series that shows a high UCH-L1 level that differs from the next
highest Session. [Site 2 Session 8 vs. Session 9, t (21)=2.10, p=0.048;
Site 3 Session 9 vs. Session 3, t (31)= 2.55, p=0.016]. Site 1 did not show
a single Session that clearly met criterion, with pairwise comparisons of
Site 1 Sessions with the greatest UCH-L1 concentrations showing no
difference (p values >0.05). Session 8 was used to represent post-blast
exposure UCH-L1 concentrations for Site 1. Arrows indicate Sessions
selected for comparison to baseline (Session 1).
analysis, which yielded R2= 0.05 and standard coefficient of 0.23
(t= 2.36, p= 0.020) (Figure 4). Six subjects were excluded from
this analysis due to missing data. There was a reliable associ-
ation between blast magnitude and UCH-L1 increase, but that
association was not strong.
In a secondary analysis, baseline UCH-L1 was compared to
UCH-L1 levels from the Session with exposure to the largest blast.
The largest blast was recorded at Site 3 on the day of Session 7
(Figure 5). The other two sites did not have a comparable day
of exposure so this analysis was conducted for Site 3 only. Of the
33 subjects enrolled at Site 3, 1 subject was not exposed to blast
FIGURE 3 |The percentage of participants showing increase in
normalized UCH-L1 from the previous day for each Session at each of
the three sites. Session 8 for Sites 1 and 2 and Session 9 for Site 3 show
that 40% or more of the subjects showed an increase in UCH-L1. Arrows
indicate Sessions selected for comparison to baseline (Session 1). No data
are shown for Session 1 in this figure because there was no prior timepoint
available to assess daily increase in UCH-L1.
FIGURE 4 | Scatterplot of individuals’ normalized UCH-L1 from the
Session that was compared to baseline in the primary analysis
(Session 8 for Sites 1 and 2, Session 9 for Site 3) expressed as a
function of the greatest peak overpressure recorded for that individual
on that day. The line represents simple linear regression.
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on Session 7 and was not included in this analysis. The remain-
ing 32 subjects were exposed to peak pressures ranging from 5.0
to 11.7 psi. This exposure magnitude differed from the exposure
in the preceding Session [t (31)= 23.98, p< 0.001]. Simple linear
regression of UCH-L1 concentration and magnitude of blast for
Session 7 showed no relation (p= 0.559).
The other secondary analysis of UCH-L1 relative to blast expo-
sure considered all available blast exposures across the three sites
by comparing the final Session with blast exposure to baseline,
regardless of UCH-L1 concentration or blast magnitude recorded
for that final Session. The final Session with blast exposure was Ses-
sion 9 for each of the three sites (see Figure 1). This evaluation of
UCH-L1 at Session 9 showed increased UCH-L1 [t (99)= 5.97,
p< 0.001] (Figure 6). Two of the three sites included a final
Session with no blast exposure (i.e., Session 10) and, thus, UCH-
L1 measurements >24 h from blast exposure, which afforded an
opportunity to examine UCH-L1 levels return to baseline when
FIGURE 5 | Mean blast magnitude [peak pressure (psi)] recorded for
each Session for each site. Error bars are standard error. Data are not
included for Session 2 at Site 3 due to the use of alternate recording
equipment in that Session. The arrow indicates the unique Session selected
for focused analysis of greatest blast magnitude on UCH-L1 concentration.
there was no acute exposure to blast. Comparison of Session 9
to Session 10 in those two Sites showed a decline in UCH-L1
concentration, t (75)= 2.53, p= 0.013.
For assessment of vestibular function corresponding to the Ses-
sions compared in the primary analysis, the Session with the great-
est level of measured UCH-L1 also showed increase in postural
sway for the test conditions with eyes open, on both firm surface,
t (97)=−2.76, p= 0.007 and dynamic surface, t (97)=−2.45,
p= 0.016 (Figure 7, left panel). Postural sway with eyes open was
also observed to increase in comparison of baseline to Session
9 (final blast exposure) but for dynamic surface condition only,
t (96)=−3.34, p= 0.001 (Figure 7, right panel). The mean value
increase for postural sway on firm surface did not meet statistical
criterion. However, these increases in postural sway from baseline
for the Sessions compared in the primary analysis and for Session
9 did not correlate with UCH-L1 increase in the same session (p
values >0.05). There was also no association for postural sway in
the eyes closed for firm surface or foam surface conditions.
In the supporting analyses of UCH-L1 and its association with
magnitude of blast exposure, the symptomology, cognitive testing,
FIGURE 6 | Mean normalized UCH-L1 for baseline and the Session with
the final blast exposure in the 2-week training protocol for each site
(i.e., Session 9). Error bars are standard error.
FIGURE 7 | Mean postural sway (standard deviation from center of
gravity) for baseline and post-blast comparison Sessions, shown for test
conditions with eyes open on each of two surfaces. Greater degree of
postural sway corresponds to worse performance. Left panel is baseline and
the post-blast Session with the greatest UCH-L1 increase (Session 8 for Sites
1 and 2, Session 9 for Site 3). Right panel is baseline and the final post-blast
Session (Session 9). All three sites are combined. Error bars are standard
error.
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and demographic data showed only one association. Among the
14 comparisons examined in the ANAM data (seven ANAM
subtests, two timepoints), only the comparison between Session
9 (final blast exposure) UCH-L1 increase and ANAM Simple
Reaction Time subtest performance decrease showed correspon-
dence, R2= 0.06 and standard coefficient of −0.25 (t=−2.43,
p= 0.017). In the ANAM TBI Battery, the Simple Reaction Time
subtest is administered twice and the second administration of
the Simple Reaction Time subtest did not show this associa-
tion, R2= 0.03 and standard coefficient of −0.16 (t=−1.56,
p= 0.123). This association was also not observed between UCH-
L1 increase and ANAM Simple Reaction Time when Session 8
was considered for Sites 1 and 2 (the timepoints with the greatest
UCH-L1 increase). The remaining ANAM subtests at the compar-
ison timepoints showed no association with UCH-L1 or showed
a positive relation (UCH-L1 increase corresponding to improve-
ment in ANAM subtest performance). There were no associations
between the blast-related UCH-L1 increases and DANA perfor-
mance, self-reported symptomology, or demographic data. When
UCH-L1 increase on the Session with maximum UCH-L1 or on
Session 9 was compared to subject characteristics of age, his-
tory of head injury, blast exposure, or breaching, the correlations
were low and did not meet criterion for statistical reliability (p
values >0.05).
DISCUSSION
The purpose of this study was to examine UCH-L1 as a marker
of neurological insult in individuals exposed to repeated low-level
blasts. The results lend only limited support to the hypothesis that
UCH-L1 measurements reflect blast-related environmental insult
to the human CNS. Direct association to an acute effect from
low-level blast was not clear, given unexplained outlier effects and
the weakness of the observed association. Overall, these findings
are consistent with a recent study of UCH-L1 in relation to sub-
concussive sports-related impacts (12). Puvenna and colleagues
observed increases in UCH-L1 in the context of participation in a
contact sport (i.e., American football) but no association between
UCH-L1 increases and measures of the degree of head impacts or
other markers of CNS injury.
In the present study, when comparing baseline to the post-
blast exposure Session with the greatest group-level UCH-L1
change, we found a correspondence between degree of UCH-
L1 increase and greater magnitude of blast exposure, but there
were clear deviations from that pattern. As exemplified in appar-
ent outliers in Figure 4, there was an individual who exhibited
more than 1000% increase from baseline in UCH-L1, yet the
magnitude of his blast exposure was <2 psi and not apparently
extraordinary. There was an individual who was exposed to blast
of more than 5 psi (a high value in this study), yet he exhibited
a decline in UCH-L1 concentration as compared to his pre-blast
exposure baseline value. It seems likely that the simple associa-
tion observed between blast and UCH-L1 in the aggregate is not
capturing important factors. A factor of principal consideration
is elapsed time between blast exposure and blood draw, which
could not be controlled in this observational paradigm. The sub-
ject cited here with exposure to blast pressure >5 psi was available
for blood draw 6 h 40 min following most recent exposure to blast.
It may be that the trauma-related temporal dynamics of UCH-
L1 are rapid enough that elapsed time is an essential variable
for useful application of UCH-L1 as a marker of low-level blast
exposure.
It also seems likely that there is an important contribution of
prior blast exposure that occurs following a short-lived timeframe
of UCH-L1 increase and decrease within 24 h of injury. When
comparing baseline levels of UCH-L1 with levels after the final
day with blast exposure in this 2-week paradigm regardless of blast
magnitude that day UCH-L1 increases were observed. However,
when comparing baseline levels of UCH-L1 to the Session with the
largest single blast exposure, there was not an association between
magnitude of blast and degree of UCH-L1 increase, at least not
acutely. The total number of days of blast exposure may be more
related to UCH-L1 increase than same-day magnitude of blast.
There was also an unclear correspondence between blast-
associated increase in UCH-L1 and the behavioral data. Two
of the four postural sway assessments showed results following
blast exposure that were consistent with performance deficit. The
other two assessments did not show such deficit, but it is rele-
vant that those two conditions were the eyes closed conditions.
Standing steady with eyes closed, regardless of supporting sur-
face, is a novel activity for humans. As such, when challenged to
do so everyday across a period of 10 days, people are likely to
improve in their eyes closed skill. It is reasonable that a minor
deficit in an eyes closed assessment of postural sway would be
masked by a practice effect. In an eyes open condition, however,
human subjects can be assumed to be at asymptote at baseline
and post-blast assessments would be more sensitive to deficits in
performance of the vestibular system. This interpretation of the
postural sway results in this study is reasonable, but, even so, the
degree of increase in postural sway following blast exposure did
not correspond to degree of UCH-L1 increase, further diminishing
inferences that can be drawn from UCH-L1 changes. The remain-
ing behavioral data provided only one association with UCH-L1
to consider. The increase in blast-related UCH-L1 was associ-
ated with decreased performance on the ANAM Simple Reaction
Time subtest in the final Session with blast exposure. In first con-
sideration, this seemed relevant in that, of the ANAM subtests,
the Simple Reaction Time subtest is regarded as of some clini-
cal utility in assessment of concussion (25). However, there were
notable inconsistencies in this association between blast-related
UCH-L1 and cognitive reaction time, specifically in the parallel
reaction time test within the same battery and the same Session
(also shown to have clinical utility in assessment of concussion)
(26), a similar assessment in the same Session (i.e., DANA Sim-
ple Reaction Time subtest), and the Simple Reaction Time subtest
on the preceding day when larger blast-related UCH-L1 increase
was observed. Further, in consideration of the 14 comparisons
examined in the ANAM cognitive testing data, a correction to sta-
tistical criterion for multiple comparisons means that the single
observed association may not be compelling. A finding of no clear
relation between the behavioral data and UCH-L1 increase was
somewhat expected, given that observation of change in behav-
ioral performance in other studies has been rare. Field testing
incurs more variability than clinical settings and can mask small
cognitive changes. Therefore, we did not expect to find behavioral
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changes relevant to clinical diagnoses or operator performance of
duties.
For these analyses of a neurotrauma biomarker among nor-
mal healthy undiagnosed individuals, it is reasonable that some
subjects would not show any change in UCH-L1 concentration
following exposure to low-level blast at any timepoint, which was
the case in this study. The low levels of blast used in training
environments do not yield injury, so, when change in UCH-L1
is observed, the key question is if that change is associated with
blast or if that change more closely corresponds to some other
variable. In these data, potential predictors of neurotrauma vul-
nerability and UCH-L1 change (age, history of head injury or
blast exposure) did not meet statistical criterion to account for
changes in UCH-L1 concentration; whereas magnitude of blast
did. It is difficult to determine contributions of individual differ-
ences to expression of UCH-L1 as there has been no study of what
constitutes normal levels in healthy young adults. Most human
studies of UCH-L1 have been with brain injured patients (27).
Additionally, based on the notion that sub-concussive behavioral
symptoms after repeated exposures may accrue to produce injury-
like symptoms is supported in populations that experience blast
(4), one would expect a history of breaching to be differentiated
by the biomarker. However, we observed no statistical difference
in UCH-L1 levels between those with a history and those without.
In the same way, UCH-L1 levels in individuals with a history of
head injury were not different than levels in those with no history
of head injury. These results suggest that while UCH-L1 may be a
marker for acute clinical injury (14), it may not differentiate based
on past sub-concussive or even concussive neurological insults.
This study was the first multi-site large sample human sub-
jects study of an acute serum-based neurotrauma biomarker
in conjunction with individualized measurement of concurrent
blast magnitudes. There were, however, limitations resulting from
the observational nature of the design and potentially from the
selection of methods to measure and analyze blast magnitude.
The approach to analysis maximized the likelihood that the pre-
dominant environmental exposure was blast overpressure, but
unknown environmental factors could not be controlled and can-
not be ruled out as influences on UCH-L1. For example, given
that UCH-L1 is expressed by other cell types, such as neurons in
the neuromuscular junction (28) and inflammatory cells (29), it is
possible that serum increases observed are related to events other
than neurological insult due to blast. Effects on the body globally
may be related to rise in peripheral levels (12, 30).
Other biomarkers may be better candidates or important addi-
tions to assess acute effects of low-level blast exposure on the
CNS, including biomarkers in cases of mild traumatic brain injury
reported in this issue (Buonora et al., under review). These poten-
tial markers include: neuron-specific enolase (NSE) (31–33) and
brain-derived neurotrophic factor (BDNF) (34, 35) as markers of
neuronal damage and recovery; peroxiredoxin 6 (PRDX6) as an
assessment of oxidative stress (36, 37); and S100 calcium binding
protein beta (S100b) as a marker of glial damage and gliosis (33,
38). Future investigations of concurrent blood marker and blast
exposure measurement should consider including these or other
additional markers, as well as establishing normal levels in healthy
young adults. Technological advances and new techniques can be
expected to improve the assay of UCH-L1, especially at concen-
trations currently below assay thresholds, which may improve the
ability to reveal associations with other parameters (such as blast
exposure), However, the brain is a complex organ and it is reason-
able that a multi-channel assessment will be more effective than a
single channel assessment.
There are multiple methods to quantify blast exposure. Aver-
aging peak pressure readings from sensors placed on the left and
right sides of the helmet reduces the fidelity of the data. However,
without accurate information on the orientation of the operator
in relation to the blast, it is impossible to know how individual
pressure sensor readings represent reflective and incident pres-
sures. Such pressure differentiation becomes even more complex
in settings with effective reflective surfaces and/or use of mul-
tiple charges in close proximity. Incident pressure readings are
inherently lower than reflected, so by averaging the readings from
the two sensors we are underestimating the overall pressure load
to the head. In the high-paced, restricted training environments
examined in this study, accurate logging of head orientation for all
participants during all training events was not feasible. Therefore,
the conservative estimates of blast exposure used in this analysis
seemed most appropriate. Furthermore, other measured elements
of the blast event, such as impulse energy, may have been supe-
rior predictors than peak pressure. However, different measures of
blast pressure are positively correlated with each other and should
yield similar variance across measures.
The objective in this study was to evaluate UCH-L1 as a
serum-based marker of low-level blast exposure. Identifying such
a serum-based biomarker will be particularly advantageous in mil-
itary settings (5). The present study does not directly support
serum-based UCH-L1 as an effective standalone marker for use
in studies of subclinical effects from low-level blast. UCH-L1 may
serve as a predictor of negative health effects from a larger magni-
tude blast than observed in the current study or as a contributory
indicator among a panel of blood-based neurotrauma biomark-
ers. Alternately, it may be that UCH-L1 could serve as a standalone
marker when assessed from cerebral spinal fluid (CSF) rather than
serum (39), but CSF was outside the scope of the current study and
not suitable as a routine assessment in a field setting. Our results
do not diminish the promise of serum-based neurotrauma bio-
markers in this domain, but further study of potential biomarkers
is required.
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